Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. This would answer questions about safety and efficacy, they said.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

AUGUST 19, 2019

The Therapeutic Goods Administration (TGA), Australia’s medicines regulatory body (akin to the FDA in the USA and EMA in Europe), is currently collecting some potentially useful information from doctors prescribing medicinal cannabis around the progress of their patients.

Medicine 45

Medicine Patients Clinical Trials Access 45

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. About Evan: Evan is an undergraduate student (undecided major) in the College of Liberal Arts at Tufts University. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Refractory paediatric epilepsy. At the same time, the outlook on cannabis research data is largely positive. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one.

Legalization 128

Legalization Patients Education Dispensary 128